Skip to main content

Table 1 Characteristics of the studies (RCTs) included in the meta-analysis

From: The quadrivalent HPV vaccine is protective against genital warts: a meta-analysis

First author (year)

Study type

Countries

Average follow-up period

Patient characteristics

Number of cases/number of patients

Number of cases/number of patients

    

Age (years)

Number of sexual partners

  
    

Mean

Range

   
    

Vaccinated groupa

Placebo groupb

  

Vaccinated group

Placebo group

Garland (2007) [20]

RCT

16 countries from Asia Pacific, Europe, North- Central- and South America

3 years

20.2 ± 1.8

20.3 ± 1.8

16–24

< 4

0/2261

48/2279

Dillner (2010) [21]

RCT

24 countries from North America, Latin America, Europe, Asia Pacific

42 months

20

16–26

< 4

2/6718

186/6647

Majewski (2009) [22]

RCT

Austria, Czech Republic, Denmark, England, Finland, France, Germany, Greece, Iceland, Ireland, Italy, Norway, Poland, Portugal, Russian Federation, Spain, and Sweden.

36 months

19.7

16–24

≤4

1/4059

90/4057

Villa (2006)

[23]

RCT

Brazil, Nordic countries, Finland, Sweden, Norway

60 months

20.2

20.0

16–23

≤4

0/214

20/209

Munoz (2010) [24]

RCT

Australia, Austria, Brazil, Canada, Colombia, Czech Republic, Denmark, Finland, Germany, Hong Kong, Iceland, Italy, Mexico, New Zealand, Norway, Peru, Poland, Puerto Rico, Russia, Singapore, Sweden, Thailand, the United Kingdom, United States

3,6 years

?

?

15–26

< 4 except Finnish women

4/4689

138/4735

Perez (2008) [25]

RCT

Brazil, Mexico, Colombia, Costa Rica, Guatemala, Peru

?

19.8 ± 3.0

20.3 ± 2.2

9–24

≤4

0/2075

9/1976

Yoshikawa (2013) [26]

RCT

Japan

23 months

22.7 ± 2.1

22.9 ± 2.1

18–26

≤4

2/400

7/376

Mikamo (2019) [16]

RCT

Japan

36 months

22.6 ± 2.1

22.6 ± 2.0

18–27

17–26

0/561

1/562

  1. RCT: randomised controlled trial
  2. a: vaccine = quadrivalent HPV vaccine (HPV types 6, 11, 16, 18)
  3. b: placebo = aluminium hydroxyphosphate sulphate adjuvant